ATC CODE
- L01BC52
INDICATIONS AND NEMLC RECOMMENDATIONS
INDICATIONS AND NEMLC RECOMMENDATIONS 1
INDICATION
- Adjuvant breast cancer.
NEMLC RECOMMENDATION
- Approved
(Cyclophosphamide plus methotrexate plus fluoro-uracil (CMF)).
REVIEW INDICATORS
- n/a
DATE RATIFIED
- 27 November 2008
INDICATIONS AND NEMLC RECOMMENDATIONS 2
INDICATION
- Adjuvant colorectal cancer.
NEMLC RECOMMENDATION
- Approved
(Fluoro-uracil plus Doxorubicin plus cyclophosphamide (FAC)).
REVIEW INDICATORS
- n/a
DATE RATIFIED
- 27 November 2008